Wedbush Downgrades Compass Therapeutics to Neutral, Lowers Price Target to $1

Benzinga Newsdesk www.benzinga.com Negative 91.2%

Neg 91.2% Neu 0% Pos 0%

Wedbush analyst Robert Driscoll downgrades Compass Therapeutics (NASDAQ:CMPX) from Outperform to Neutral and lowers the price target from $5 to $1.